Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis

• Main Authors: Stéphanie Bui (Author), Alexandra Masson (Author), Raphaël Enaud (Author), Léa Roditis (Author), Gaël Dournes (Author), François Galode (Author), Cyrielle Collet (Author), Emmanuel Mas (Author), Jeanne Languepin (Author), Michael Fayon (Author), Fabien Beaufils (Author), Marie Mittaine (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g.,...